MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kassel, O.
Right arrow Articles by Frossard, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kassel, O.
Right arrow Articles by Frossard, N.

Vol. 54, Issue 6, 1073-1079, December 1998

Up- and Down-Regulation by Glucocorticoids of the Constitutive Expression of the Mast Cell Growth Factor Stem Cell Factor by Human Lung Fibroblasts in Culture

Olivier Kassel, Fabien Schmidlin, Catherine Duvernelle, Frédéric de Blay, and Nelly Frossard

Institut National de la Santé et de la Recherche Médicale U425, Neuroimmunopharmacologie Pulmonaire, Faculté de Pharmacie, 67401 Illkirch Cedex, France

Stem cell factor (SCF) is a major mast cell growth factor that promotes differentiation and chemotaxis of mast cells and inhibits their apoptosis. SCF therefore may be involved in diseases associated with an increased number of tissue mast cells such as asthma, for which the major treatment is glucocorticoids. In this study, we evaluated the effect of the glucocorticoid budesonide on the constitutive expression of SCF by human lung fibroblasts in primary culture. Budesonide (0.1 µM) induced a time-dependent biphasic effect on SCF mRNA and protein production. A short treatment (2.5-10 hr) induced an inhibition of SCF protein accumulation (-58% at 2.5 hr) and mRNA expression (-69% at 2.5 hr), associated with an accelerated decay of SCF mRNA and with a decrease in SCF gene transcription observed by nuclear run-on assay. Longer treatment (24-72 hr) led to increases in SCF protein accumulation (+64% at 48 hr) and mRNA expression (+125% at 24 hr) as a consequence of transcriptional activation. Similar effects of a decrease followed by an increase in SCF production were observed using another glucocorticoid, dexamethasone. Overall, our results show that glucocorticoids potently regulate SCF expression in human lung fibroblasts, successively decreasing and increasing SCF mRNA levels according to treatment duration. Such time-dependent modulation of SCF levels may explain some current discrepant findings about the effects of glucocorticoids on SCF production and may have functional consequences during glucocorticoid treatment, such as asthma therapy.


Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Eur Respir JHome page
V. Freund, F. Pons, V. Joly, E. Mathieu, N. Martinet, and N. Frossard
Upregulation of nerve growth factor expression by human airway smooth muscle cells in inflammatory conditions
Eur. Respir. J., August 1, 2002; 20(2): 458 - 463.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
C. Olgart and N. Frossard
Human lung fibroblasts secrete nerve growth factor: effect of inflammatory cytokines and glucocorticoids
Eur. Respir. J., July 1, 2001; 18(1): 115 - 121.
[Abstract] [Full Text] [PDF]


Home page
Obstet GynecolHome page
J. L. BARTHA, R. ROMERO-CARMONA, R. COMINO-DELGADO, F. ARCE, and J. ARRABAL
Alpha-Fetoprotein and Hematopoietic Growth Factors in Amniotic Fluid
Obstet. Gynecol., October 1, 2000; 96(4): 588 - 592.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Hopfner, M. Mousli, J.-M. Jeltsch, A. Voulgaris, Y. Lutz, C. Marin, J.-P. Bellocq, P. Oudet, and C. Bronner
ICBP90, a Novel Human CCAAT Binding Protein, Involved in the Regulation of Topoisomerase II{{alpha}} Expression
Cancer Res., January 1, 2000; 60(1): 121 - 128.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics